Cynthia A Bossie

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
    Cynthia A Bossie
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:79. 2011
  2. doi request reprint Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
    Am J Psychiatry 166:691-701. 2009
  3. doi request reprint Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
    Ibrahim Turkoz
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08650, USA
    J Affect Disord 150:17-22. 2013
  4. doi request reprint A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Rd E12604, Titusville, NJ 08560, USA
    J Clin Psychiatry 71:587-98. 2010
  5. pmc Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
  6. doi request reprint Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560 0200, USA
    J Affect Disord 120:193-9. 2010
  7. ncbi request reprint An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 77:129-39. 2005
  8. doi request reprint Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA
    Early Interv Psychiatry 4:64-78. 2010
  9. doi request reprint Psychotic symptoms in patients with bipolar mania
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey 08560, United States
    J Affect Disord 111:164-9. 2008
  10. doi request reprint Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia
    Wayne Macfadden
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
    Int Clin Psychopharmacol 25:75-82. 2010

Detail Information

Publications30

  1. pmc Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
    Cynthia A Bossie
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:79. 2011
    ..These post-hoc analyses addressed two commonly encountered clinical issues regarding the initiation dosing: the time to onset of efficacy and the associated tolerability...
  2. doi request reprint Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
    Am J Psychiatry 166:691-701. 2009
    ..The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization...
  3. doi request reprint Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
    Ibrahim Turkoz
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08650, USA
    J Affect Disord 150:17-22. 2013
    ..This analysis explored the relationship between ratings on HAM-D-17 or YMRS and those on the depressive or manic subscale of CGI-S for schizoaffective disorder (CGI-S-SCA)...
  4. doi request reprint A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Rd E12604, Titusville, NJ 08560, USA
    J Clin Psychiatry 71:587-98. 2010
    ..This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder...
  5. pmc Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
    ..To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology...
  6. doi request reprint Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560 0200, USA
    J Affect Disord 120:193-9. 2010
    ..This post-hoc analysis evaluated the effects of paliperidone extended-release (ER) in patients with schizophrenia and prominent affective symptoms...
  7. ncbi request reprint An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 77:129-39. 2005
    ..This analysis assessed TD by defined research criteria in patients receiving long-acting, injectable risperidone...
  8. doi request reprint Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA
    Early Interv Psychiatry 4:64-78. 2010
    ..Effective early and persistent antipsychotic treatment in recently diagnosed schizophrenia may positively impact long-term outcomes. Paliperidone extended-release (ER) was assessed in this population...
  9. doi request reprint Psychotic symptoms in patients with bipolar mania
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey 08560, United States
    J Affect Disord 111:164-9. 2008
    ..Psychosis has been identified in as many as 68% of patients with bipolar mania. This analysis identified psychotic symptoms in these patients...
  10. doi request reprint Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia
    Wayne Macfadden
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
    Int Clin Psychopharmacol 25:75-82. 2010
    ..2%), anxiety (12.3 vs. 17.3%), and influenza (10.5 vs. 5.3%). These findings confirm the benefit of RLAT in patients with schizophrenia and suggest that earlier treatment with long-acting preparations is associated with better outcomes...
  11. doi request reprint Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
    J Clin Psychopharmacol 30:487-95. 2010
    ..Paliperidone ER improved psychotic and affective symptoms both as monotherapy and as an adjunct to MS/AD. No new safety findings were observed in this population...
  12. ncbi request reprint Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
    Robert A Lasser
    Global Medical Strategy, Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
    Schizophr Res 77:215-27. 2005
    ..Recently proposed criteria for remission (mild or less on multiple core-symptom ratings for at least 6 months) have been applied to a 1-year study of long-acting risperidone injection...
  13. doi request reprint Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone
    Jennifer Kern Sliwa
    Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, USA
    Schizophr Res 132:28-34. 2011
    ..To examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone...
  14. ncbi request reprint Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 21:233-40. 2006
    ..Associations were noted between patient-rated quality of life and specific symptom domains, but not insight...
  15. ncbi request reprint Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial
    Robert A Lasser
    Janssen Psychiatry, LLC, Titusville, NJ 08560, USA
    Int J Neuropsychopharmacol 8:427-38. 2005
    ..Psychotic patients considered stable but symptomatic with oral risperidone treatment showed further improvements in symptom ratings and extrapyramidal dysfunction during a year of bi-weekly injections of long-acting risperidone...
  16. pmc Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, NJ, USA
    BMC Psychiatry 6:45. 2006
    ..Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia...
  17. doi request reprint Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs LLC, Titusville, NJ, USA
    Int Clin Psychopharmacol 23:209-15. 2008
    ..4% with placebo. In patients who had received risperidone previously but remained sufficiently symptomatic for enrollment, paliperidone ER was significantly more effective than placebo in reducing symptoms and producing functional gains...
  18. ncbi request reprint Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder
    Natalie Ciliberto
    Medical Services CNS, Medical Affairs Division, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Int Clin Psychopharmacol 20:207-12. 2005
    ..ESRS scores were low throughout the study, and no significant impact of race was observed. Overall rates of AEs were similar among the racial groups. Race did not appear to impact the efficacy and tolerability of long-acting risperidone...
  19. ncbi request reprint Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia
    Georges M Gharabawi
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, NJ 08560, USA
    Schizophr Res 77:119-28. 2005
    ....
  20. ncbi request reprint Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder
    Robert Lasser
    Janssen Pharmaceutical Products, LP, Titusville, NJ, USA
    J Affect Disord 83:263-75. 2004
    ..Data from a large study (n=725), which included schizoaffective patients to assess the effect of long-acting risperidone, are presented...
  21. doi request reprint Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Dong Jing Fu
    aMedical Affairs bMedical Information, Janssen Scientific Affairs, LLC cBiostatistics, B and P, Janssen Research and Development, LLC, Titusville, New Jersey, USA
    Int Clin Psychopharmacol 29:45-55. 2014
    ..In patients with recently diagnosed schizophrenia, the tolerability and efficacy of PP and RLAI were generally similar over 13 weeks...
  22. pmc Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
    Larry Alphs
    CNS Medical Affairs, LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 9:341-50. 2013
    ....
  23. pmc Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
    Jennifer Kern Sliwa
    Janssen Scientific Affairs LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 8:375-85. 2012
    ....
  24. ncbi request reprint Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
    Robert A Lasser
    Janssen Medical Affairs, LLC, Titusville, New Jersey 08560, USA
    Int J Geriatr Psychiatry 19:898-905. 2004
    ..Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery...
  25. ncbi request reprint Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
    J Autism Dev Disord 37:367-73. 2007
    ..7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism...
  26. pmc Role of paliperidone extended-release in treatment of schizoaffective disorder
    Carla M Canuso
    External Innovation Neuroscience Therapeutic Area, Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 6:667-79. 2010
    ..To the best of our awareness, these pooled data provide the largest data set of patients with schizoaffective disorder, and extend our knowledge of disease characteristics and treatment response...
  27. pmc Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
    Ibrahim Turkoz
    Ortho McNeil Janssen Scientific, Affairs, LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 4:949-58. 2008
    ..1% inverse effect. Path analysis indicated that paliperidone ER has a direct effect on negative symptoms. Negative symptom improvement also was indirectly mediated via changes in positive and depressive symptoms...
  28. pmc A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia
    Wayne Macfadden
    Dr Macfadden was with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis Dr Macfadden currently is Medical Director at Princeton Medical Institute, Princeton, New Jersey Drs Ma and Haskins are with Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey and Drs Bossie and Alphs are with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey
    Psychiatry (Edgmont) 7:23-31. 2010
    ....
  29. pmc Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
    Ann Gen Psychiatry 10:12. 2011
    ..abstract:..
  30. ncbi request reprint Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
    Robert A Lasser
    Janssen Medical Affairs, LLC 1125 Trenton Harbourton Road, Office A20904, Titusville, NJ 08560 0200, USA
    Eur Psychiatry 19:219-25. 2004
    ..This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics...